Demonstrated Long-Term Safety Through 52 Weeks
The safery of Adbry was was demonstrated in 5 robust clinical trials that included nearly 2000 patients1,3
Approved for patients ages 12 years and older. Click here for different pediatric patient dosing.
//
DOSING & ADMINISTRATION
In adults, Adbry provides the flexibility to treat with every-other-week or once-monthly dosing after 16 weeks of treatment1
Adbry has the flexibility of:
after 16 weeks of treatment1
Initial dose: 600 mg
- 4 prefilled syringes
Maintenance dose: 300 mg
- 2 prefilled syringes every other week, or every 4 weeks may be considered in adult patients <100 kg (220 lbs) who achieve clear or almost clear skin after 16 weeks of treatment
- Adbry is intended for use under the guidance of a healthcare provider. A patient may self-inject Adbry after training in subcutaneous injection technique using the prefilled syringe. Provide proper training to patients and/or caregivers on the preparation and administration of Adbry prior to use according to the “Instructions for Use”1
- For the initial 600 mg dose, administer each of the four Adbry 150 mg injections at different injection sites within the same body area1
- For the subsequent 300 mg doses, administer the two Adbry 150 mg injections at different injection sites within the same body area1
Important Administration Instructions1
- Administer subcutaneous injection into the thigh or abdomen, except for the 2 inches (5 cm) around the navel. The upper arm can also be used if a caregiver administers the injection
- Rotate the body area with each subsequent set of injections. DO NOT inject Adbry into skin that is tender, damaged, bruised, or scarred
Learn more about Adbry dosing information
Adbry Administration for Adults
Not an actual patient. Individual results may vary.
Adbry Administration for Children 12 Years and Older
Not an actual patient. Individual results may vary.
//
HOW SUPPLIED
Single-dose prefilled syringe
- Adbry does not contain preservatives
- Adbry injection is a sterile, clear to opalescent, colorless to pale yellow solution, supplied in single-dose prefilled syringe with a 27-gauge, 1/2-inch needle and a needle guard
- Each prefilled syringe delivers 150 mg/mL of Adbry
- None of the components of the prefilled syringe or the needle guard are made with natural rubber latex
Not actual size
Adbry is available in pack sizes containing 2 or 4 prefilled syringes with needle guard1
- Two cartons (multipack) containing four prefilled syringes (NDC 50222-346-04)
- One carton containing two prefilled syringes (NDC 50222-346-02)
Storage and Handling1
- Adbry does not contain preservatives. Discard any unused product remaining in the prefilled syringe.
- Store refrigerated at 36°F to 46°F (2°C to 8°C) in the original carton in order to protect from light.
- If necessary, prefilled syringes may be kept at room temperature up to 86ºF (30ºC) for a maximum of 14 days in the original carton. Do not store above 86ºF (30ºC). If the carton needs to be removed permanently from refrigerator, the date of removal may be recorded on the outer carton in the space provided. After removal from the refrigerator, Adbry must be used within 14 days or discarded.
- Do not expose the prefilled syringe to heat or direct sunlight.
- Do not freeze. Do not shake.
